PROGENITER (Pathogen Response Optimization by GENeratIng ThErapeutics Rationally), a project under the umbrella of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) at The University of British Columbia (UBC), has been awarded more than $6 million by the British Columbia Knowledge Development Fund (BCKDF). This funding will support the research team, led by Dr. Sriram Subramaniam, to leverage advanced antibody discovery tools including artificial intelligence in discovering and producing clinical-grade antibodies capable of combating current and emerging pandemic threats.

Investments from the BCKDF support the development and scale-up of research infrastructure and technology. Projects funded under the CIEBH consortium will enable researchers at UBC to partner with biotechnology and pharmaceutical industry collaborators to increase Canadian capacity to develop and manufacture patient-ready therapies.

Learn more: $31M provincial investment boosts Canada’s Immuno-Engineering and Biomanufacturing Hub at UBC

About PROGENITER

PROGENITER is a University of British Columbia-affiliated, nationally recognized, multi-year research program to enable the rapid design, engineering, and production of antibody leads against present and future viral diseases to ensure that Canada is prepared for the next pandemic. PROGENITER is a key component of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH). Our interdisciplinary team of researchers, students, staff, and industry partners work together to discover, test, and advance therapeutics targeting infectious diseases at an accelerated pace. This mission aligns with CIEBH’s vision for rapidly responding to new health threats and Canada’s Biomanufacturing and Life Sciences Strategy (BLSS).